Content about Biotechnology

August 27, 2013

Lawmakers in California have passed a bill that would restrict the use of follow-on versions of biotech drugs known as biosimilars, according to published reports.

NEW YORK — Lawmakers in California have passed a bill that would restrict the use of follow-on versions of biotech drugs known as biosimilars, according to published reports.

August 22, 2013

A bill under consideration by California's state legislature contains provisions that would place restrictions on pharmacists' ability to dispense knock-off versions of biotech drugs, drawing opposition from the generic pharmaceutical lobby and the state's pension fund for government employees.

SACRAMENTO, Calif. — A bill under consideration by California's state legislature contains provisions that would place restrictions on pharmacists' ability to dispense knock-off versions of biotech drugs, drawing opposition from the generic pharmaceutical lobby and the state's pension fund for government employees.

August 20, 2013

Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

NEW YORK — Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

August 8, 2013

The world is turning generic. That's the takeaway from the latest trends in the drug industry, according to IMS Health.

The world is turning generic. That's the takeaway from the latest trends in the drug industry, according to IMS Health. In 2012, according to the healthcare industry analytics firm, dollar sales of drugs fell by 1% to $325.7 billion, but prescriptions grew by 1.2% as generic drugs' share of total drugs dispensed grew to nearly 83%.

July 15, 2013

The Consumer Healthcare Products Association announced that Lisa Murphy Early will join the association as VP finance and administration and CFO.

WASHINGTON — The Consumer Healthcare Products Association on Monday announced that Lisa Murphy Early will join the association as VP finance and administration and CFO. 

“Lisa is a highly experienced association executive with extensive financial, managerial and strategic planning experience in the non-profit and for-profit sectors,” stated CHPA president and CEO Scott Melville. 

July 12, 2013

The creation of a clear approval pathway for biosimilar drugs remains a daunting task for the Food and Drug Administration, despite the fact that it's prescribed by law through the Patient Protection and Affordable Care Act. But when those lower-priced, generic versions of some staggeringly expensive bioengineered medicines do finally come to market, they're likely to have a profound effect on the nation's outlays for specialty pharmaceuticals.

The creation of a clear approval pathway for biosimilar drugs remains a daunting task for the Food and Drug Administration, despite the fact that it's prescribed by law through the Patient Protection and Affordable Care Act. But when those lower-priced, generic versions of some staggeringly expensive bioengineered medicines do finally come to market, they're likely to have a profound effect on the nation's outlays for specialty pharmaceuticals.

June 3, 2013

Another bill to limit dispensing of biosimilars lost Monday, this time in Illinois.

WASHINGTON — Another bill to limit dispensing of biosimilars lost Monday, this time in Illinois.

The state's legislature voted not to advance S.B. 1934, supported by such biotech companies as Amgen and Genentech, which would slow patients' access to knock-off versions of biotech drugs by restricting pharmacists' ability to dispense them. Illinois is the 13th state to defeat such a bill; a similar bill died in Texas' state legislature last week.

May 30, 2013

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

May 29, 2013

Texas has become the latest state to defeat a bill that critics say would limit the reach of knock-off versions of biotech drugs.

WASHINGTON — Texas has become the latest state to defeat a bill that critics say would limit the reach of knock-off versions of biotech drugs.

May 23, 2013

Kathy Ireland, CEO and chief designer of Kathy Ireland Worldwide and women’s health advocate, is collaborating with board-certified surgeon Dr. David Scharp in bringing to the beauty market a stem cell-derived product brand called Stemáge.

LOS ANGELES — Kathy Ireland, CEO and chief designer of Kathy Ireland Worldwide and women’s health advocate, is collaborating with board-certified surgeon Dr. David Scharp in bringing to the beauty market a stem cell-derived product brand called Stemáge.

They note that the unique aspect of the natural skin rejuvenation system is that it targets visible signs of aging through the proprietary use of human Mesenchymal stem cell derivatives, not stem cells but rather active ingredients or derivatives of which stem cells are comprised.

May 7, 2013

The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.

LONDON — The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.

The study, by British market research firm Visiongain, forecast that the $2.445 billion market size marked more than 20% of growth from 2012 and would account for about 2% of the overall market for biologics. The market is expected to grow rapidly through 2023 as biosimilars hit the market in the United States and European Union.

May 6, 2013

Florida's state legislature approved a bill last week that will allow pharmacists to substitute biosimilars for brand name biotech drugs.

NEW YORK — Florida's state legislature approved a bill last week that will allow pharmacists to substitute biosimilars for brand name biotech drugs.

The bill, which was approved last Tuesday and is scheduled to take effect on July 1, institutes requirements for pharmacists to substitute biosimilars when they are determined to be biosimilar to and interchangeable with the brand name product, while also requiring the state board of pharmacy to maintain a current list of interchangeable products.

April 29, 2013

Electronic health platform Fitango is creating a three-part action plan to support childhood immunizations, the company said.

NEW YORK — Electronic health platform Fitango is creating a three-part action plan to support childhood immunizations, the company said Monday.

Fitango announced the release of its new series of Preventative Actionplans, broken up according to age, respectively titled "Tracking Your Child's Vaccinations (0 - 2)," "Tracking Your Child's Vaccinations (4 - 6)" and "Tracking Your Child's Vaccinations (7 - 18)."

April 25, 2013

Galderma, whose brands include Cetaphil, and The American Academy of Dermatology have announced the creation of the American Academy of Dermatology Translational Biotechnology Fellowship.

CHAUMBURG, Ill., and SOPHIA ANTIPOLIS, France — Galderma, whose brands include Cetaphil, and The American Academy of Dermatology have announced the creation of the American Academy of Dermatology Translational Biotechnology Fellowship.

April 24, 2013

Generic drug maker Hospira marked its fifth year marketing knock-off versions of biotech drugs in Europe Wednesday as it presented at the 2013 Biotechnology Industry Organization International Convention this week.

CHICAGO — Generic drug maker Hospira marked its fifth year marketing knock-off versions of biotech drugs in Europe Wednesday as it presented at the 2013 Biotechnology Industry Organization International Convention this week.

The drug maker said it delivered more than 5 million doses of biosimilar medicines to patients in Europe and Australia. The convention includes multiple sessions devoted to such topics as biosimilar regulatory approval, manufacturing and market formation, the company said.

April 10, 2013

Legislation designed to limit the use of biosimilars has met defeat in Maryland.

WASHINGTON — Legislation designed to limit the use of biosimilars has met defeat in Maryland.

April 4, 2013

A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

WASHINGTON — A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

The Florida Senate Committee on Health Policy passed S.B. 732, sending it to the full state senate. The legislation would require pharmacists to inform doctors when a follow-on biologic was substituted for a brand-name biotech drug. The bill is similar to one signed into law last month by Virginia Gov. Bob McDonnell.

April 2, 2013

Frazier Healthcare announced its acquisition of AndersonBrecon, the contract pharmaceutical packaging business and wholly owned subsidiary of AmerisourceBergen.

PHILADELPHIA — Frazier Healthcare on Tuesday announced its acquisition of AndersonBrecon, the contract pharmaceutical packaging business and wholly owned subsidiary of AmerisourceBergen. Packaging Coordinators, a provider of pharmaceutical and biotechnology packaging services and Frazier Healthcare portfolio company, will combine with AndersonBrecon to offer services on a global scale.

March 29, 2013

The Food and Drug Administration is seeking comment from drug makers and others concerning formal meetings between the agency and companies looking to market follow-on biologics.

SILVER SPRING, Md. — The Food and Drug Administration is seeking comment from drug makers and others concerning formal meetings between the agency and companies looking to market follow-on biologics.

March 29, 2013

Pharmaca Integrative Pharmacy on Thursday expanded its immunization offering to include travel vaccinations along with a comprehensive list of health services related to traveling abroad.

BOULDER, Colo. — Pharmaca Integrative Pharmacy on Thursday expanded its immunization offering to include travel vaccinations along with a comprehensive list of health services related to traveling abroad. 

Pharmaca patients can now schedule an appointment for any of the following vaccinations: hepatitis A and B, tetanus, typhoid, meningitis, Tdap, yellow fever (though not in Colorado locations), varicella and rabies. Pharmaca still offers vaccinations for flu, shingles, whooping cough and pneumonia on a walk-in basis.

March 8, 2013

A new bill (HB 365) in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.

A new bill (HB 365) in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports. The Sarasota Herald-Tribune reported that the Health Quality Subcommittee of the Florida House of Representatives approved a bill that would allow for substitution while requiring pharmacists to notify prescribing physicians within five days and require the doctor and pharmacist to maintain a record for at least four years. A similar bill (SB 732) is pending in the Florida Senate, according to reports.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

February 19, 2013

A new bill in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.

NEW YORK — A new bill in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.

The Sarasota Herald-Tribune reported that the Health Quality Subcommittee of the Florida House of Representatives approved a bill that would allow for substitution while requiring pharmacists to notify prescribing physicians within five days and require the doctor and pharmacist to maintain a record for at least four years.

February 8, 2013

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

NEW YORK — Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

January 23, 2013

Cytos Biotechnology will regain rights to an experimental vaccine against nicotine addiction that it had licensed to Novartis, Cytos said Wednesday.

SCHLIEREN, Switzerland — Cytos Biotechnology will regain rights to an experimental vaccine against nicotine addiction that it had licensed to Novartis, Cytos said Wednesday.

The company said that Novartis would discontinue the project, known as NIC002. Cytos granted Novartis a license for NIC002 in 2007, but phase-2 trial results in October 2009 indicated that the vaccine spurred the development of nicotine-specific antibodies in patients, but did not increase smoking cessation.